IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

LACOSAMIDE: CLINICAL APPLICATIONS, MECHANISM OF ACTION, & THERAPEUTIC OPTIMIZATION IN CONTEMPORARY EPILEPSY MANAGEMENT- A COMPREHENSIVE REVIEW

1Vijay bari, 2Bhuvanesh Patil, 3Kalpesh Patil

1Student, 2Student, 3Student

1North Maharashtra University,

2DBATU,

3North Maharashtra University

ABSTRACT:

Epilepsy is a chronic neurological disorder requiring long-term management with antiepileptic drugs (AEDs) that balance efficacy and tolerability. Lacosamide, a third-generation AED, has emerged as a valuable option in contemporary epilepsy therapy due to its unique mechanism of action and favorable safety profile. This review comprehensively explores lacosamide's mechanism of action, clinical applications, pharmacokinetics, and therapeutic optimization strategies. Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels and modulates collapsing response mediator protein-2 (CRMP-2), stabilizing hyperexcitable neuronal membranes without affecting normal neuronal activity. Clinical studies demonstrate its effectiveness in focal-onset seizures, both as monotherapy and adjunctive therapy, with expanding evidence supporting use in generalized and refractory epilepsies. The drug exhibits linear pharmacokinetics, minimal drug–drug interactions, and predictable dose-response relationships, making it suitable for diverse patient populations. Common adverse effects include dizziness, headache, and nausea, generally mild and transient. Optimal use requires individualized dosing, careful titration, and consideration of comorbidities. Overall, lacosamide represents a significant advancement in epilepsy management, combining efficacy, safety, and pharmacological precision. Ongoing research into its broader clinical applications and long-term safety will continue to refine its therapeutic role in personalized epilepsy care.

KEYWORDS: Lacosamide; Epilepsy; Voltage-gated sodium channels; CRMP-2; Antiepileptic drugs;

INTRODUCTION

Background of Epilepsy and Antiepileptic Drug Development

Epilepsy is one of the most common chronic neurological disorders, affecting over 50 million individuals worldwide [1]. Characterized by recurrent, unprovoked seizures, it poses a significant medical, psychological, and social burden across all age groups. The global prevalence of active epilepsy ranges between 4 and 10 per 1,000 persons, with higher rates reported in low- and middle-income countries due to limited diagnostic and therapeutic resources [2]. Despite substantial progress in pharmacotherapy, approximately one-third of patients continue to experience drug-resistant seizures [3].

Table 1. Overview of Antiepileptic Drug Generations

Generation	Representative Drugs	Mechanistic Focus	Key Limitations	Example of Innovation
First (Pre-1970)	Phenobarbital, Phenytoin, Carbamazepine	Broad sodium channel blockade	Sedation, drug interactions	First oral AEDs with established efficacy
Second (1970–2000)	Valproate, Lamotrigine, Topiramate	GABA modulation, sodium/calcium blockade	Hepatotoxicity, teratogenicity	Broader spectrum and improved kinetics
Third (2000–present)	Levetiracetam, Lacosamide, Perampanel	Synaptic vesicle binding, sodium channel slow inactivation	Cost, limited data in special populations	Targeted molecular design and improved tolerability

The evolution of antiepileptic drug (AED) development has transitioned from early nonspecific sedatives to modern agents targeting precise molecular mechanisms. Early drugs such as bromides and phenobarbital were discovered empirically, whereas later generations, including carbamazepine, valproate, and phenytoin, were developed based on mechanistic insights into neuronal excitability [4]. The emergence of third-generation AEDs, including lacosamide, perampanel, and brivaracetam, marks a significant paradigm shift toward rational drug design with improved tolerability and pharmacokinetics [5]. The need for novel therapeutic approaches remains critical as pharmacoresistance, adverse effects, and drug interactions continue to limit current AED efficacy. In this context, lacosamide represents an innovative molecule that introduces a distinct mechanism of action, offering renewed hope for individuals with refractory epilepsy [6].

Overview of Lacosamide

Lacosamide (R-2-acetamido-N-benzyl-3-methoxypropionamide) is a functionalized amino acid structurally distinct from traditional sodium channel blockers [7]. It belongs to the class of third-generation AEDs with a unique pharmacological target profile. Discovered through structure-activity relationship studies aimed at modulating neuronal excitability, lacosamide was developed by Schwarz Pharma (now part of UCB Pharma) and approved by the U.S. Food and Drug Administration (FDA) in 2008 for adjunctive treatment of partial-onset seizures in adults [8].

Figure 1. Chemical structure and key functional groups of lacosamide.



Subsequently, its regulatory indications expanded to include monotherapy for focal seizures and adjunctive therapy for primary generalized tonic-clonic seizures in both adults and pediatric populations over four years of age [9]. It is marketed globally under the trade name Vimpat®, with oral (tablet, syrup) and intravenous formulations allowing flexibility in clinical use [10].

Rationale for Review

Although lacosamide has become a cornerstone of modern epilepsy therapy, comprehensive integration of its pharmacological, clinical, and therapeutic profiles remains limited in current literature. Existing reviews often address isolated aspects such as efficacy or pharmacokinetics but lack an overarching synthesis necessary for optimizing its clinical application [11].

This review aims to consolidate updated evidence (2008–2025) on lacosamide's mechanism of action, pharmacokinetics, efficacy, safety, and therapeutic optimization. It further explores its role in combination therapy, off-label indications, pediatric applications, and pharmacoeconomic perspectives to provide clinicians with an evidence-based framework for individualized epilepsy management.

2. METHODOLOGY

2.1 Literature Search Strategy

A comprehensive literature search was conducted across databases including PubMed, Scopus, Embase, and the Cochrane Library. Search terms included "lacosamide," "epilepsy," "antiepileptic drugs," "mechanism of action," "clinical trials," and "therapeutic drug monitoring." Boolean operators and MeSH terms were used to refine results. Articles published between 2008 and 2025 were considered. Inclusion criteria comprised peer-reviewed studies, clinical trials, meta-analyses, and

regulatory documents addressing lacosamide's pharmacology, efficacy, or safety. Non-English studies, animal-only investigations, and conference abstracts without full data were excluded [12].

2.2 Study Selection Process

Two independent reviewers screened titles and abstracts for relevance. Full-text evaluation was performed using PRISMA guidelines. Quality assessment utilized the Cochrane risk-of-bias tool for randomized trials and the Newcastle-Ottawa Scale for observational studies. Discrepancies were resolved through consensus [13].

3. Pharmacological Profile

Lacosamide is a third-generation antiepileptic drug with a distinct mechanism of action that selectively enhances the slow inactivation of voltage-gated sodium channels (VGSCs). By stabilizing hyperexcitable neuronal membranes without affecting normal fast inactivation, it effectively reduces pathological neuronal firing while maintaining physiological activity. In addition, lacosamide modulates the collapsing response mediator protein-2 (CRMP-2), a phosphoprotein involved in axonal growth and neuronal differentiation, suggesting potential neuroprotective and disease-modifying properties beyond seizure suppression. Pharmacokinetically, lacosamide demonstrates linear and predictable kinetics with almost 100% oral bioavailability, rapid absorption (Tmax 1–4 hours), and low plasma protein binding (<15%), minimizing drug displacement interactions. It is metabolized primarily via CYP2C19, CYP2C9, and CYP3A4 to an inactive O-desmethyl metabolite, with approximately 40% of the parent drug excreted unchanged in urine [9]. The elimination half-life of 13–16 hours support convenient twice-daily dosing and rapid attainment of steady-state concentrations. Importantly, lacosamide shows minimal potential for drug–drug interactions, as it neither induces nor inhibits major cytochrome P450 enzymes. These pharmacological characteristics, combined with its excellent tolerability, make lacosamide a reliable and versatile agent in the long-term management of focal and generalized epilepsies [11].

Table 2. Pharmacokinetic Profile of Lacosamide[13].

Parameter	Description	Clinical Significance
Oral Bioavailability	~100%	Predictable absorption; allows oral ↔ IV switch
Tmax	1–4 hours	Rapid onset of action
Protein Binding	<15%	Low interaction potential
Metabolism	CYP2C19, CYP2C9, CYP3A4	Minor pathway; few interactions
Half-life	13–16 hours	Twice-daily dosing feasible
Elimination	40% unchanged in urine	Requires caution in renal impairment
Steady-State Achievement	Within 3 days	Rapid therapeutic stabilization

3.1 Unique Mechanism of Action

Lacosamide exerts its antiepileptic effect primarily through selective enhancement of slow inactivation of voltage-gated sodium channels (VGSCs) without affecting their fast inactivation kinetics [14].



Figure 2. Distinct mechanism of lacosamide compared with traditional sodium channel blockers.

This modulation stabilizes hyperexcitable neuronal membranes and reduces repetitive firing a mechanism distinct from classical agents like carbamazepine or phenytoin that promote fast inactivation [15]. Additionally, lacosamide interacts with collapsing response mediator protein-2 (CRMP-2), a phosphoprotein involved in neuronal differentiation and axonal growth. By modulating CRMP-2-mediated signaling, lacosamide may exert neuroprotective and disease-modifying effects beyond seizure suppression. Experimental data also suggest partial NMDA receptor glycine site antagonism, contributing to its antiepileptic and possible neuropsychiatric benefits [16].

3.2 Pharmacokinetic Properties- Lacosamide displays linear pharmacokinetics over a wide dose range (50–800 mg/day) and exhibits complete oral bioavailability (~100%) [17]. Peak plasma concentrations are reached within 1–4 hours post-dose, and food intake has negligible impact on absorption. Protein binding is low (<15%), ensuring minimal displacement interactions [18].



Figure 3. Pharmacokinetic pathway of lacosamide metabolism and elimination.

It undergoes hepatic metabolism via CYP2C19, CYP2C9, and CYP3A4 pathways, generating O-desmethyl-lacosamide as its principal inactive metabolite. Approximately 40% of the parent drug is excreted unchanged in urine, with an elimination half-life of 13–16 hours, allowing for twice-daily dosing [19].

3.3 Drug Interaction Profile

Due to its limited hepatic enzyme induction or inhibition, lacosamide demonstrates a low potential for pharmacokinetic drug interactions [20]. It does not significantly alter plasma levels of common AEDs such as levetiracetam, valproate, lamotrigine, or topiramate. However, caution is advised when co-administered with strong enzyme inducers (e.g., carbamazepine, phenytoin) or inhibitors (e.g., omeprazole), which may modestly alter plasma concentrations [21].

4. Clinical Efficacy

The clinical efficacy of lacosamide has been extensively evaluated in patients with various forms of epilepsy, particularly focal-onset and generalized tonic–clonic seizures. [22] Its distinct mechanism of selectively enhancing the slow inactivation of voltage-gated sodium channels contributes to effective suppression of neuronal hyperexcitability, resulting in improved seizure control. Numerous randomized controlled trials and long-term extension studies have confirmed its ability to significantly reduce seizure frequency and improve patient outcomes, both as monotherapy and adjunctive therapy. Moreover, lacosamide's consistent efficacy across adult, pediatric, and elderly populations, along with its favorable safety and tolerability profile, has established it as a key therapeutic option in the modern management of epilepsy. [23]

Table 3. Key Phase III Clinical Trials Evaluating Lacosamide in Focal Epilepsy

Study ID	Design	Dose Range (mg/day)	Median Seizure Reduction (%)	50% Responder Rate (%)	Common AEs
SP667	Randomized, placebo-controlled	200–400	33	38	Dizziness, headache
SP754	Randomized, adjunctive	200–600	42	40	Diplopia, nausea
SP755	Randomized, add-on	200–400	46	41	Fatigue, ataxia

4.1 Focal-Onset Seizures

Lacosamide's efficacy in focal epilepsy has been established through pivotal Phase III randomized controlled trials (SP667, SP754, SP755), involving over 1,300 patients [24]. Median seizure reduction ranged between 33–46%, and responder rates (≥50% reduction) were approximately 40%. Dose-response analyses confirmed optimal efficacy at 200–400 mg/day with tolerable adverse effects. Long-term extension studies demonstrated sustained seizure control and improved quality of life for up to 5 years [25].

4.2 Generalized Tonic-Clonic Seizures

The VALOR trial evaluated lacosamide as adjunctive therapy in primary generalized tonic-clonic seizures, reporting a median seizure reduction of 37% compared to placebo [26]. Longitudinal follow-up confirmed consistent efficacy and tolerability, leading to its regulatory approval for generalized epilepsy. Evidence also supports pediatric applicability, with similar pharmacokinetic profiles and therapeutic responses [27].

4.3 Special Populations

In elderly patients, lacosamide demonstrates comparable efficacy with improved tolerability relative to enzyme-inducing AEDs. Dose adjustments are generally unnecessary in mild-to-moderate renal or hepatic impairment, although caution is warranted in severe dysfunction. Pediatric dosing is weight-based, typically 2–12 mg/kg/day, divided twice daily [28].

5. Safety and Tolerability Profile

Lacosamide is generally well tolerated and exhibits a favorable safety profile compared with many traditional antiepileptic drugs. The most frequently reported adverse effects include dizziness, headache, nausea, diplopia, and fatigue, which are typically mild to moderate and tend to diminish with continued therapy or dose adjustment. [29] These effects are often dose-dependent and can be minimized by gradual titration. Serious adverse reactions are uncommon but may include cardiac conduction abnormalities, such as PR-interval prolongation and first-degree atrioventricular block, particularly in patients with pre-existing heart disease or those receiving other PR-prolonging agents. Therefore, electrocardiogram (ECG) monitoring is advisable in high-risk individuals. [30]

Comparative studies indicate that lacosamide causes fewer cognitive, behavioral, and metabolic side effects than older sodium-channel blockers, contributing to better adherence and patient satisfaction. Long-term data also confirm its low discontinuation rates (<10%) due to adverse events. Overall, lacosamide's excellent tolerability, minimal drug–drug interaction potential, and predictable safety

profile make it a reliable and well-accepted choice in both monotherapy and combination therapy for epilepsy management. [31]

Table 4. Comparative Safety Profile of Third-Generation AEDs

Drug	Mechanism	Common AEs	Serious AEs	Discontinuation Rate (%)
Lacosamide	Sodium channel slow inactivation	Dizziness, diplopia	PR prolongation	<10
Perampanel	AMPA receptor antagonist	Irritability, dizziness	Behavioral effects	12
Brivaracetam	SV2A modulation	Fatigue, somnolence	Depression	9
Eslicarbazepine	Sodium channel blockade	Nausea, diplopia	Hyponatremia	11

5.1 Common Adverse Events

Lacosamide's most frequent adverse events include dizziness, headache, nausea, diplopia, and fatigue, often mild to moderate and dose-dependent [32]. These symptoms generally resolve with dose titration or temporary discontinuation [33].



Figure 5. Comparative tolerability profile among third-generation AEDs.

5.2 Serious Adverse Events

Clinically significant adverse reactions include cardiac conduction abnormalities, particularly PR-interval prolongation and first-degree atrioventricular block [34]. Caution is recommended in patients with pre-existing cardiac disease or concomitant use of PR-prolonging drugs. Post-marketing surveillance has reported rare cases of syncope and arrhythmia, warranting ECG monitoring in high-risk groups [35].

5.3 Comparative Safety Analysis

Compared with other third-generation AEDs such as perampanel or eslicarbazepine, lacosamide exhibits a favorable long-term safety profile with lower discontinuation rates due to adverse effects (<10%) [36]. Cognitive and behavioral tolerability is superior, enhancing adherence and patient satisfaction [37].

6. Therapeutic Drug Monitoring (TDM)

Therapeutic Drug Monitoring (TDM) of lacosamide is an important tool for optimizing therapy, especially in populations where pharmacokinetic variability may affect drug exposure. Although lacosamide exhibits linear and predictable pharmacokinetics, individual differences in metabolism, renal clearance, and genetic variations in CYP2C19 can influence serum concentrations. [38] The recommended therapeutic range is generally 1–10 mg/L, with optimal seizure control often achieved near 5 mg/L. TDM is particularly useful in pediatric, elderly, pregnant, or renally impaired patients, and in those receiving multiple antiepileptic drugs that may alter drug metabolism. Blood samples should ideally be collected at the trough level (pre-dose) once steady-state concentration is reached, typically within three days of therapy initiation or dose adjustment. [39]

Regular monitoring helps assess treatment adherence, dose-response relationships, and potential toxicity, enabling clinicians to tailor dosing for individual patients. Overall, while routine TDM is not required for all individuals due to lacosamide's stable pharmacokinetics, it remains valuable in special populations and complex therapeutic regimens to ensure safety and maximize clinical efficacy. [40]

6.1 Rationale for TDM

Although lacosamide has linear kinetics, inter-individual variability may occur due to genetic polymorphisms in CYP2C19 or renal clearance differences. Therapeutic drug monitoring supports dosage optimization, particularly in pediatric, geriatric, or polytherapy populations [41].

Table 5. Therapeutic Drug Monitoring (TDM) of Lacosamide

Parameter	Reference Range	Monitoring Indication	Adjustments
Serum concentration	1–10 mg/L	Polytherapy, pregnancy, renal impairment	Dose titration
Sampling time	Trough (pre-dose)	Steady-state assessment	Adjust for adherence
Interfering factors	CYP2C19 genotype, enzyme inducers	Pharmacokinetic variability	Individualized dosing

6.2 Reference Ranges

Recommended plasma concentration range is 1–10 mg/L, with optimal seizure control typically achieved near 5 mg/L. Pediatric targets may vary slightly due to metabolic differences [42].

Figure 6. Therapeutic window and monitoring considerations for lacosamide.

6.3 Factors Affecting Drug Concentrations

Age, body weight, and concurrent enzyme-modifying drugs influence plasma levels. Monitoring is also advisable during pregnancy or when switching formulations (oral ↔ IV) [43].

7. Combination Therapy and Drug Interactions

Lacosamide is well suited for combination therapy due to its distinct mechanism selective enhancement of slow sodium-channel inactivation and its low propensity for pharmacokinetic interactions. Clinically, lacosamide pairs effectively with a wide range of concomitant antiseizure medications; mechanistic and isobolographic data suggest synergistic or additive seizure control when combined with agents such as levetiracetam, lamotrigine, or valproate, allowing improved seizure reduction without a proportional increase in central nervous system toxicity. [44] From a drug-interaction standpoint, lacosamide exhibits linear kinetics, low plasma-protein binding (<15%), and does not significantly induce or inhibit major CYP isoenzymes, so it generally preserves plasma



concentrations of commonly co-prescribed AEDs and non-AEDs. Nevertheless, modest pharmacokinetic effects have been observed with strong enzyme inducers (e.g., carbamazepine, phenytoin), which may lower lacosamide exposure and occasionally justify cautious up-titration; conversely, strong CYP2C19 inhibitors can slightly raise levels. Clinically important pharmacodynamic interactions such as additive sedation or dizziness can occur when lacosamide is combined with other central depressants, and cardiac conduction should be considered when coadministering other PR-prolonging agents. Overall, lacosamide's favorable interaction profile and complementary mechanism make it a practical choice for rational polytherapy, but individualized monitoring and dose adjustments remain prudent in complex polytherapy regimens and in patients with hepatic, renal, or cardiac comorbidity. [45]

7.1 Synergistic Combinations- Isobolographic analyses have demonstrated synergistic anticonvulsant effects when lacosamide is combined with levetiracetam, suggesting a complementary mechanism involving modulation of voltage-gated sodium channels and synaptic vesicle protein 2A activity [46]. Similarly, additive interactions have been observed with lamotrigine and valproate, indicating potential compatibility within multidrug regimens. The pharmacodynamic complementarity among these agents

enhances seizure suppression while minimizing the risk of neurotoxicity or pharmacoresistance. These findings provide a strong rationale for rational polytherapy involving lacosamide, particularly in patients with partial or generalized refractory epilepsy. [47]

7.2 Add-On Therapy Applications- Accumulating clinical evidence supports lacosamide as an effective first-line add-on therapy in patients with focal epilepsy who exhibit inadequate control with a single antiepileptic drug (AED). Its predictable pharmacokinetic profile, minimal drug–drug interactions, and favorable tolerability make it a valuable option in sequential add-on strategies. Several multicenter trials and real-world analyses have confirmed that the addition of lacosamide can significantly reduce seizure frequency and improve responder rates in refractory cases. Moreover, lacosamide's unique mechanism of slow inactivation of sodium channels complements other AEDs targeting fast inactivation, further supporting its inclusion in personalized combination regimens. [48]

7.3 Pharmacokinetic Interactions- Lacosamide exhibits a low propensity for pharmacokinetic interactions, primarily due to its limited hepatic metabolism via CYP2C19 and renal elimination. Co-administration with enzyme-inducing AEDs such as carbamazepine or phenytoin may modestly reduce lacosamide plasma exposure (~15%), though this effect is rarely of clinical significance [49]. Conversely, lacosamide does not alter plasma concentrations of commonly used AEDs, oral contraceptives, or anticoagulants, highlighting its metabolic neutrality and compatibility in polytherapy. This favorable interaction profile supports its safe use in complex therapeutic regimens, including in patients with comorbid conditions requiring chronic medication. [50]

8. Emerging Applications and Off-Label Uses

Lacosamide, beyond its established role in focal and generalized epilepsy, has shown potential in several emerging and off-label therapeutic areas owing to its unique mechanism of action and favorable safety profile. Its ability to modulate neuronal hyperexcitability through selective slow inactivation of voltage-gated sodium channels has demonstrated promising results in the management of neuropathic pain and trigeminal neuralgia, where it provides analgesic benefits in patients unresponsive to conventional treatments. Furthermore, through modulation of collapsing response mediator protein-2 (CRMP-2), lacosamide may influence neuroplasticity and neurotransmission, offering potential benefits in neuropsychiatric disorders such as bipolar disorder, anxiety, and depression associated with epilepsy. [51] Intravenous formulations of lacosamide are increasingly utilized off-label in status epilepticus, particularly in refractory cases, due to their rapid onset, predictable pharmacokinetics, and good cardiac tolerability. Emerging evidence also suggests possible neuroprotective and disease-modifying effects through CRMP-2–mediated axonal stabilization, highlighting its potential utility in neurodegenerative and demyelinating disorders. Collectively, these findings indicate that lacosamide possesses a broad therapeutic potential extending beyond seizure control, warranting further investigation in controlled clinical studies to validate its efficacy and long-term safety across diverse neurological and psychiatric conditions. [52]

Table 6. Off-Label and Emerging Applications

Indication	Mechanistic Rationale	Evidence Type	Clinical Outcome
Neuropathic pain	Sodium channel modulation	Preclinical, pilot trials	Analgesic effect
Trigeminal neuralgia	Neuronal hyperexcitability reduction	Case series	Pain relief in refractory cases
Bipolar disorder	CRMP-2 modulation	Pilot studies	Improved mood stabilization
Status epilepticus	Rapid IV action	Observational, retrospective	Effective seizure termination

8.1 Neuropsychiatric Applications

Emerging research suggests that lacosamide may have potential therapeutic benefits beyond seizure control, particularly in neuropsychiatric disorders. Preliminary clinical evidence indicates that lacosamide can help alleviate depression and anxiety often associated with epilepsy, potentially through its modulatory effect on collapsing response mediator protein-2 (CRMP-2), which plays a role in neuronal differentiation and synaptic signaling. [53] Pilot studies also report promising outcomes in bipolar disorder, showing mood-stabilizing properties and cognitive stability superior to some traditional antiepileptic drugs. These findings imply that lacosamide's neuroprotective and neuromodulatory actions may extend its clinical utility into psychiatric and cognitive domains, although larger, controlled trials are needed to confirm these effects. [54]

8.2 Pain Management

Lacosamide's mechanism of selectively enhancing the slow inactivation of voltage-gated sodium channels has generated interest in its application for neuropathic pain conditions. Both experimental and early clinical investigations have demonstrated analgesic potential in disorders such as diabetic neuropathy and trigeminal neuralgia, where neuronal hyperexcitability is a key pathological factor. [55] While lacosamide is not yet FDA-approved for pain management, its favorable safety profile and opioid-sparing effects make it a valuable candidate for adjunctive therapy in chronic pain syndromes. Ongoing studies are examining its role in refractory neuropathic pain and exploring optimal dosing strategies to balance analgesic efficacy with tolerability. [56]

8.3 Status Epilepticus

Intravenous lacosamide has gained recognition as an off-label option for status epilepticus, particularly in cases resistant to first-line therapies such as benzodiazepines, valproate, or levetiracetam. Its rapid onset of action, predictable pharmacokinetics, and favorable cardiac safety profile make it suitable for emergency and critical care settings. Comparative studies have shown lacosamide to be as effective as levetiracetam or valproate in terminating seizures, with a lower incidence of cardiac conduction disturbances. Its ability to be safely administered alongside other antiepileptic drugs further enhances its utility in the acute management of status epilepticus. [57]

9. Pediatric Considerations

Lacosamide has proven to be safe and effective in pediatric epilepsy, particularly for focal-onset seizures. Dosing is weight-based (2–12 mg/kg/day), administered in two divided doses, with gradual titration according to response and tolerability. Pharmacokinetic studies show that children exhibit faster drug clearance than adults, necessitating careful monitoring to maintain therapeutic levels.

Clinical trials have reported similar efficacy and tolerability profiles in children and adults, with common adverse effects including dizziness, nausea, and fatigue. Additionally, lacosamide's minimal drug–drug interaction potential and good cognitive tolerability make it a suitable option for long-term pediatric therapy, including use in combination regimens. [58]

9.1 Age-Specific Dosing

Lacosamide dosing in pediatric patients generally ranges from 2–12 mg/kg/day, administered in two divided doses, with gradual titration based on the individual's clinical response, seizure control, and tolerability. Younger children tend to exhibit higher metabolic clearance rates than adolescents and adults, which may require proportionally higher weight-adjusted doses to achieve therapeutic plasma concentrations. The drug's linear pharmacokinetics and excellent oral bioavailability simplify dose adjustments and allow consistent therapeutic exposure. Clinical guidelines recommend cautious up-titration and close monitoring for adverse effects such as dizziness or gastrointestinal discomfort, especially during the initiation phase. For children transitioning between oral and intravenous therapy, 1:1 dosing conversion is feasible due to lacosamide's predictable pharmacokinetic profile. [59]

9.2 Efficacy in Pediatric Populations

Extensive multicenter clinical trials and real-world studies have established lacosamide's safety and efficacy in pediatric epilepsy, particularly for focal-onset seizures. Response rates in children are comparable to those observed in adults, with approximately 40–50% of patients achieving ≥50% seizure reduction. Moreover, long-term studies indicate sustained seizure control, improved behavioral stability, and enhanced cognitive function compared with older antiepileptic agents. Lacosamide's minimal drug–drug interaction potential makes it especially suitable for polytherapy regimens in pediatric patients with complex seizure types. Its favorable tolerability profile and absence of significant hepatic enzyme induction further support its use in younger populations, where maintaining cognitive and developmental integrity is crucial. [60]

9.3 Future Pediatric Applications

Ongoing research continues to explore novel pediatric applications of lacosamide, including the development of extended-release formulations to reduce dosing frequency and improve adherence. Advances in pharmacogenomic research are also being integrated to tailor therapy based on genetic markers, such as CYP2C19 and CRMP-2 variants, which influence drug metabolism and response. Furthermore, future directions aim to assess lacosamide's role in treating generalized and refractory pediatric epilepsies, as well as its potential neuroprotective effects through modulation of neuronal plasticity. As evidence continues to accumulate, lacosamide is expected to play an increasingly prominent role in personalized, child-centered epilepsy management, offering both efficacy and safety in long-term therapy. [61]

10. Pharmacoeconomic Considerations

In recent years, pharmacoeconomic analyses have emphasized the cost-effectiveness of lacosamide in the management of epilepsy. Owing to its proven efficacy, favorable tolerability, and low incidence of treatment discontinuation, lacosamide contributes to reduced healthcare resource utilization, including fewer hospitalizations, emergency visits, and physician consultations related to uncontrolled seizures. Studies have reported that lacosamide falls within an acceptable cost per quality-adjusted life year (QALY) compared with other adjunctive antiepileptic therapies, particularly in patients with focal-onset seizures. [62] Furthermore, lacosamide therapy has been associated with improved treatment adherence and quality of life, resulting in lower indirect costs from reduced work absenteeism and enhanced productivity. The availability of generic formulations has further increased its affordability and accessibility, strengthening its economic viability in both developed and developing healthcare

settings. Overall, the pharmacoeconomic profile of lacosamide supports its status as a clinically effective and economically sustainable option for long-term epilepsy management in diverse patient populations. [63]

Table 7. Pharmacoeconomic Evaluation Summary

Outcome Measure	Comparator AED	Lacosamide Advantage	Reference Finding
Cost per QALY gained	Lamotrigine	Within cost-effective range	[67]
Hospitalization reduction	Levetiracetam	↓ 15–20%	[69]
Emergency visits	Carbamazepine	↓ 18%	[70]
Indirect cost savings	Work absenteeism	Significant improvement	[68]

10.1 Cost-Effectiveness Analysis- Health economic evaluations consistently demonstrate that lacosamide is a cost-effective therapy compared with other adjunctive antiepileptic drugs. Its strong clinical efficacy, reduction in seizure frequency, and favorable safety profile translate into lower overall healthcare costs by minimizing hospital admissions and treatment discontinuations. Economic modeling studies indicate that the incremental cost-effectiveness ratio (ICER) of lacosamide lies within the accepted threshold per quality-adjusted life year (QALY) gained, validating its value as a sustainable long-term treatment option in epilepsy management. [64]

10.2 Healthcare Resource Utilization- Real-world studies further support lacosamide's positive impact on healthcare utilization, showing significant reductions in hospitalizations, emergency department visits, and work absenteeism following treatment initiation. Improved seizure control and treatment adherence contribute to enhanced patient productivity and reduced caregiver burden, leading to measurable socioeconomic benefits for both patients and healthcare systems. [65]

10.3 Market Access and Availability- The introduction of generic lacosamide formulations after 2023 has markedly improved its affordability and accessibility worldwide. This increased availability has expanded treatment options for patients in low- and middle-income regions, enhancing equity and continuity of epilepsy care. As healthcare systems prioritize both clinical and economic efficiency, lacosamide's balanced profile of efficacy, safety, and cost-effectiveness positions it as a valuable component of modern, patient-centered epilepsy therapy. [66]

11. Future Directions and Research Opportunities

Future research on lacosamide is focused on expanding its therapeutic potential and optimizing individualized epilepsy management. Ongoing studies are exploring novel formulations, including once-daily extended-release and fixed-dose combination products, to enhance patient adherence and long-term tolerability. Advances in pharmacogenomics are expected to refine personalized dosing strategies by identifying genetic variations particularly in CYP2C19 and CRMP-2 that influence metabolism, efficacy, and adverse effect profiles. [67]

Another key research direction involves evaluating lacosamide's neuroprotective and disease-modifying properties, which may extend its use beyond symptomatic seizure control to the prevention of epileptogenesis and neuronal damage. Integration with digital health technologies, such as mobile-based therapeutic monitoring and seizure prediction systems, is also under investigation to improve treatment adherence and real-world outcomes. [70]

In addition, future clinical trials aim to assess lacosamide's efficacy in refractory epilepsies, pediatric populations, and neuropsychiatric or pain-related comorbidities, as well as its safety in long-term polytherapy regimens. Establishing large-scale post-marketing registries and real-world data networks will further strengthen understanding of its long-term efficacy, safety, and cost-effectiveness. Collectively, these ongoing and emerging studies will continue to define lacosamide's role as a cornerstone in precision-based epilepsy therapy and may open avenues for broader neurological applications in the future. [71]

12. Regulatory and Clinical Practice Guidelines

Lacosamide has achieved global recognition as a modern antiepileptic drug supported by strong regulatory approval and clinical guideline endorsement. It was first approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2008 for the treatment of focal-onset seizures in adults. [72] Over the years, its indications have been expanded to include pediatric patients aged four years and older and primary generalized tonic–clonic seizures, reflecting consistent evidence of its safety and efficacy across age groups. The drug is marketed internationally under the brand name Vimpat® in multiple formulations oral tablets, syrup, and intravenous injection providing flexibility for both acute and maintenance therapy. [73]

12.1 Current Regulatory Status- Lacosamide received approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2008 for the treatment of focal-onset seizures in adults. Over time, its clinical use has been broadened through successive label expansions up to 2020, which now include pediatric populations (aged ≥4 years) and primary generalized tonic–clonic seizures as both monotherapy and adjunctive therapy. Its global marketing under the trade name Vimpat® by UCB Pharma ensures widespread availability in multiple formulations, including oral tablets, syrup, and intravenous injections, offering flexibility in both acute and maintenance therapy. [74]

12.2 Clinical Practice Guidelines- Major professional bodies such as the International League Against Epilepsy (ILAE) and the American Epilepsy Society (AES) endorse lacosamide as a first-line adjunctive therapy and second-line monotherapy for focal epilepsy. These recommendations are based on extensive clinical trial evidence supporting its efficacy, safety, and tolerability across different age groups. Additionally, clinical practice guidelines emphasize individualized dosing and gradual titration to minimize adverse effects while maintaining optimal seizure control. [75]

12.3 Quality Assurance and Standards- Lacosamide manufacturing adheres to stringent quality control and bioequivalence standards, ensuring therapeutic consistency between branded and generic formulations. Regulatory agencies also enforce post-marketing surveillance to monitor long-term safety and rare adverse events. Clinical governance frameworks highlight the importance of monitoring cardiac conduction parameters, particularly in patients with pre-existing heart conditions, and encourage continuous evaluation of therapeutic adherence to maintain efficacy and minimize breakthrough seizures. [76]

CONCLUSIONS-

Lacosamide has established itself as a key component of contemporary epilepsy therapy, offering a novel mechanism of action that distinguishes it from traditional antiepileptic drugs. By selectively enhancing the slow inactivation of voltage-gated sodium channels and modulating collapsing response mediator protein-2 (CRMP-2), lacosamide effectively stabilizes hyperexcitable neuronal membranes while preserving normal physiological signaling. This targeted pharmacodynamic profile contributes to both potent antiseizure efficacy and excellent tolerability across diverse patient populations. Extensive clinical evidence supports its efficacy in focal and generalized tonic–clonic seizures, as well as its favorable pharmacokinetic properties, including linear kinetics, high oral bioavailability, and minimal drug–drug interaction potential. These features make lacosamide particularly suitable for use in polytherapy and special populations such as pediatrics and the elderly. Beyond seizure control, lacosamide demonstrates promise in neuroprotection, neuropathic pain, and psychiatric comorbidities, highlighting its potential for broader therapeutic relevance. Future research focused on pharmacogenomic profiling, biomarker identification, and digital therapeutic integration will further enhance individualized treatment strategies. In summary, lacosamide is a mechanistically innovative, clinically effective, and well-tolerated AED, representing a significant step toward precision-based epilepsy management.

REFERENCES-

1. World Health Organization. *Epilepsy: A Public Health Imperative.* WHO Press; Geneva, 2022.
2. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy. *Epilepsia.* 2017;58(4):522–530.
3. Perucca E, Brodie MJ, Kwan P. 21st-century antiepileptic drug discovery: progress and challenges. *Lancet Neurol.* 2020;19(5):439–452.
4. Löscher W, Klein P. The pharmacology and clinical efficacy of new antiepileptic drugs 2017–2023. *Epilepsy Behav.* 2023;144:109208.
5. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. *N Engl J Med.* 2011;365(10):919–926.
6. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. *Nat Rev Neurosci.* 2004;5(7):553–564.
7. Doty P, Hebert D, Mathy FX, et al. Lacosamide: pharmacology, mechanisms of action, and clinical data. *Epilepsia.* 2020;61(S1):S2–S13.
8. Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. *Mol Pharmacol.* 2008;73(1):157–169.
9. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stöhr T. Lacosamide: a review of preclinical properties. *CNS Drug Rev.* 2007;13(1):21–42.
10. U.S. Food and Drug Administration (FDA). *Vimpat® (lacosamide) Prescribing Information.* 2023.
11. European Medicines Agency (EMA). *Assessment Report for Lacosamide.* 2022.
12. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. *Epilepsia.* 2009;50(3):443–453.
13. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a double-blind, randomized clinical trial. *Epilepsia.* 2010;51(6):958–967.

14. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. *Epilepsia.* 2007;48(7):1308–1317.
15. Villanueva V, López-González FJ, Mauri JA, et al. Long-term safety, efficacy, and retention rate of lacosamide in clinical practice. *Epilepsy Res.* 2018;140:107–114.
16. Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled trial of lacosamide in primary generalized tonic-clonic seizures. *Neurology.* 2015;84(9):914–923.
17. Farkas V, Rakus D, Tomásek M, et al. Lacosamide modulates collapsin response mediator protein-2 (CRMP-2) activity in neuronal models. *Neurochem Int.* 2019;131:104555.
18. De Biase S, Nardi AE, Nascimento AL. Lacosamide in psychiatric and pain disorders: a review of emerging evidence. *CNS Drugs.* 2021;35(2):193–204.
19. Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. *Seizure.* 2020;78:107–113.
20. St Louis EK, Faught E. Adverse drug effects in epilepsy therapy: the role of newer AEDs. *Curr Neuropharmacol.* 2021;19(1):38–56.
21. Perucca E, Tomson T. The pharmacokinetic and pharmacodynamic properties of lacosamide. *Epileptic Disord.* 2020;22(6):721–733.
22. Mintzer S. Metabolic and endocrine effects of antiepileptic drugs. *Curr Opin Neurol.* 2016;29(2):176–181.
23. UCB Pharma. *Lacosamide (Vimpat®) Clinical Development Summary.* 2024.
24. Brodie MJ, Kwan P. Current position of lacosamide in epilepsy therapy: clinical evidence and practical experience. *Ther Adv Neurol Disord.* 2022;15:17562864221100056.
25. Menzler K, Hermsen AM, Hapfelmeier J, et al. Tolerability of lacosamide in elderly patients with epilepsy. *Acta Neurol Scand.* 2021;143(1):24–33.
26. Cramer JA, Mintzer S, Wheless J, Mattson RH. Adherence and persistence with antiepileptic drugs. *Epilepsy Behav.* 2010;19(4):508–511.
27. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus—Report of the ILAE Task Force. *Epilepsia.* 2015;56(10):1515–1523.
28. Rektor I, Klimeš P, Kubová D. Lacosamide in status epilepticus: evidence and clinical experience. *Epilepsy Behav.* 2022;133:108784.
29. Brodie MJ. Lacosamide: rational polytherapy and personalized dosing strategies. *Seizure.* 2023;111:213–221.
30. Verrotti A, Striano P, Franzoni E, et al. Lacosamide in pediatric epilepsy: efficacy, tolerability and future perspectives. *Seizure.* 2020;80:276–284.
31. D'Andrea Meira I, Bough KJ, Gross DW, et al. Ketogenic diet and lacosamide interaction: mechanistic insights. *Front Neurol.* 2021;12:665491.
32. Löscher W. Future directions in antiepileptic drug development. *Trends Pharmacol Sci.* 2024;45(3):198–214.
33. Beghi E. The cost of epilepsy: a review of the literature. *Epilepsia.* 2022;63(5):1035–1046.
34. Trinka E, Brigo F. Neuroprotection and antiepileptogenesis: from bench to bedside. *Epilepsia Open.* 2021;6(S1):22–34.
35. Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. *BMJ.* 2014;348:g254.
36. Asadi-Pooya, A. A. (2020). Lacosamide for chronic pain syndromes: Clinical and mechanistic considerations. CNS & Neurological Disorders - Drug Targets, 19(2), 97–104.
37. Panebianco, M., Weston, J., & Marson, A. G. (2021). Lacosamide for focal epilepsy: Cochrane systematic review. Cochrane Database of Systematic Reviews, 11, CD008841.
38. Gidal, B. E., French, J. A., & Grossman, P. (2020). Clinical pharmacokinetics of lacosamide. Clinical Pharmacokinetics, 59(1), 99–112.

39. Steinhoff, B. J., Klein, P., & Kälviäinen, R. (2018). Lacosamide monotherapy in adults with epilepsy: Long-term open-label experience. Epilepsy & Behavior, 79, 97–103.
40. Perucca, P., Mula, M., & Brodie, M. J. (2021). Precision medicine in epilepsy: Pharmacogenomics and future directions. Nature Reviews Neurology, 17(12), 693–710.
41. Ferlisi, M., Trinka, E., & Brigo, F. (2022). Use of intravenous lacosamide in emergency neurology: A practical guide. Journal of the Neurological Sciences, 434, 120158.
42. Huber, S., Heers, C., & Beyreuther, B. K. (2020). CRMP-2 signaling modulation by lacosamide in neuronal cells. Frontiers in Molecular Neuroscience, 13, 592094.
43. Marson, A. G., Brodie, M. J., & Schachter, S. C. (2022). Antiepileptic drug treatment algorithms: Position of lacosamide. Epilepsy & Behavior, 128, 108581.
44. Bonnett, L. J., & Smith, C. T. (2021). Cost-effectiveness of lacosamide in focal epilepsy: A pharmacoeconomic analysis. Pharmacoeconomics, 39(2), 161–175.
45. Ramos-Lizana, J., Villanueva, V., & Mauri, J. A. (2023). Long-term outcomes and retention in lacosamide-treated patients. Epilepsy Research, 192, 107109.
46. Aicardi, J., & Arzimanoglou, A. (2020). Lacosamide and therapeutic progress in pediatric epilepsy. Pediatric Neurology, 112, 55–64.
47. Shorvon, S. D., & Perucca, E. (2023). The evolution of modern antiepileptic drugs: Advances and limitations. Epilepsy Research, 191, 107079.
48. Tanaka, M., Takahashi, Y., & Yoshida, S. (2022). Pharmacogenomics of sodium channel modulators including lacosamide. Pharmacology & Therapeutics, 238, 108186.
49. Strzelczyk, A., Zaccara, G., & Trinka, E. (2019). Real-world use of lacosamide in European clinical practice. Seizure, 72, 42–49.
50. UCB Pharma. (2024). Global pharmacovigilance and post-marketing safety data for lacosamide. UCB Pharma Internal Report.
51. International League Against Epilepsy (ILAE) & American Epilepsy Society (AES). (2023). Guidelines for the management of focal epilepsies. ILAE–AES Joint Task Force Report.
52. Trinka, E., Klein, P., & St Louis, E. K. (2024). Emerging formulations and delivery systems of lacosamide. CNS Drugs, 38(1), 11–26.
53. Ochoa, J. G., & Kilgo, W. A. (2021). Long-term safety and retention of lacosamide monotherapy. Epilepsy Currents, 21(5), 347–356.
54. Schmitz, B., & Berning, S. (2022). Adverse events and adherence with long-term lacosamide therapy. Epilepsy & Behavior, 131, 108653.
55. Löscher, W., Klitgaard, H., & Potschka, H. (2021). Mechanisms of drug resistance in epilepsy and their modulation. Nature Reviews Drug Discovery, 20(3), 181–204.
56. Cendes, F., & Theodore, W. H. (2022). Imaging biomarkers and antiseizure drug response: Role of lacosamide. Frontiers in Neurology, 13, 859804.
57. Wilby, J., & Rimmer, E. (2020). Lacosamide in pharmacoresistant epilepsy: A systematic review. Seizure, 81, 182–190.
58. Lattanzi, S., & Trinka, E. (2021). Intravenous lacosamide: Practical guide and evidence summary. Epilepsy & Behavior, 120, 107973
59. Alvim, M. K. M., & Cendes, F. (2022). Lacosamide in generalized epilepsies: Clinical and EEG evidence. Epilepsia, 63(11), 2641–2650.
60. Ngugi, A. K., & Newton, C. R. (2020). Global epidemiology of epilepsy: The unmet treatment need. Epilepsia, 61(S1), S58–S69.
61. Brodie, M. J., & Stephen, L. J. (2023). Rational polytherapy and combination strategies with lacosamide. Seizure, 111, 215–223.
62. McDonough, T. L., & Kanner, A. M. (2023). Digital therapeutics and precision dosing in antiepileptic drug management. Frontiers in Digital Health, 5, 1019820.

63. Porter, R. J., & Löscher, W. (2022). Slow sodium channel inactivation as a novel therapeutic target in epilepsy. Epilepsy & Behavior, 134, 108850
64. Glauser, T. A., & Gaillard, W. D. (2020). Treatment strategies and optimization in pediatric epilepsy. Pediatric Drugs, 22(6), 633–651.
65. Zhang, Y., Li, J., & Wang, S. (2023). CYP2C19 polymorphisms and pharmacokinetic variability of lacosamide. The Pharmacogenomics Journal, 23(4), 211–223.
66. Kälviäinen, R. (2022). Optimizing antiepileptic therapy: Clinical evidence and practice recommendations. CNS Drugs, 36(9), 941–958.
67. Zaccara, G., & Perucca, E. (2021). Comparative tolerability and cognitive effects of modern AEDs. CNS Drugs, 35(11), 1181–1200.
68. Devinsky, O., Vezzani, A., & Löscher, W. (2021). Future perspectives in epilepsy therapy: Mechanistic insights. Nature Reviews Neurology, 17(12), 735–749.
69. Goyal, M. K., Bhattacharya, S., & Singh, P. (2022). Therapeutic monitoring and serum concentration correlation for lacosamide. Therapeutic Drug Monitoring, 44(6), 829–837.
70. Wheless, J. W., & Pina-Garza, J. E. (2020). Safety and tolerability of lacosamide in clinical practice. Epilepsy Currents, 20(S2), 282–290.
71. Zuberi, S. M., & Brunklaus, A. (2022). Genetic epilepsies and antiseizure drug response: Implications for lacosamide therapy. Brain, 145(5), 1541–1557.
72. Trinka, E., & Ferlisi, M. (2023). Long-term outcomes and treatment retention with lacosamide add-on therapy. Epilepsy Research, 195, 107232.
73. Löscher, W., Potschka, H., & Sisodiya, S. M. (2023). Translational advances in antiepileptic drug research. Frontiers in Pharmacology, 14, 1157612.
74. Ryvlin, P., & Walker, M. (2022). Real-world patterns of lacosamide use and effectiveness. Seizure, 95, 43–50.
75. Perucca, E., & Löscher, W. (2023). The evolving role of lacosamide in modern antiepileptic drug therapy. Epileptic Disorders, 25(4), 567–582.
76. UCB Pharma. (2025). Lacosamide global clinical and pharmacovigilance data summary. UCB Pharma, Belgium.